Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study

• Published in: Scientific reports 2023-11, Vol.13 (1), p.20629-20629, Article 20629
• Main Authors: Sazuka, Tomokazu, Matsushita, Yuto, Sato, Hiroaki, Osawa, Takahiro, Hinata, Nobuyuki, Hatakeyama, Shingo, Numakura, Kazuyuki, Ueda, Kosuke, Kimura, Takahiro, Takahashi, Masayuki, Tanaka, Hajime, Kawasaki, Yoshihide, Kurahashi, Toshifumi, Kato, Takuma, Fujita, Kazutoshi, Miyake, Makito, Kojima, Takahiro, Kitamura, Hiroshi, Miyake, Hideaki, Ichikawa, Tomohiko
• Format: Article
• Language: English
• Subjects: 631/67; 692/308; 692/4017; 692/4025; 692/4028; 692/499; Adverse events; Anilides - adverse effects; Cancer immunotherapy; Carcinoma, Renal Cell - pathology; Combination therapy; Disease control; East Asian People; Humanities and Social Sciences; Humans; Kidney cancer; Kidney Neoplasms; Liver diseases; Metastases; multidisciplinary; Oncology; Protein-tyrosine kinase; Renal cell carcinoma; Retrospective Studies; Risk factors; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-48087-4

Immuno-oncology (IO) combination therapy is utilized as a first-line systemic treatment for advanced renal cell carcinoma. However, evidence supporting the use of cabozantinib after IO combination therapy is lacking. We retrospectively analyzed patients who received second-line cabozantinib after IO combination therapy using the Japanese Urological Oncology Group (JUOG) database. In total, 254 patients were enrolled in the JUOG global study, and 118 patients who received second-line cabozantinib comprised the study cohort. The objective response rate, disease control rate, second-line cabozantinib progression-free survival (PFS), and overall survival from second-line for overall were 32%, 75%, 10.5 months, and not reached, respectively, for first-line IO-IO therapy were 37%, 77%, 11.1 months, and not reached, respectively, versus 24%, 71%, 8.3 months, and not reached, respectively, for first-line IO-tyrosine kinase inhibitor therapy. In univariate and multivariate analyses, discontinuation of first-line treatment because of progressive disease and liver metastasis were independent risk factors for PFS. All-grade adverse events occurred in 72% of patients, and grade 3 or higher adverse events occurred in 28% of patients. Second line-cabozantinib after first-line IO combination therapy for advanced renal cell carcinoma was expected to be effective after either IO-IO or IO-TKI treatment and feasible in real-world practice.